NLA at AHA

Are you attending the AHA Scientific Sessions in Orlando? We have put together a list of relevant sessions and presentations that may be of interest to you. Many of these sessions, including the NLA Master’s Summit on HoFH, feature NLA members as presenters or moderators. We encourage all those in attendance to support the NLA and clinical lipidology with their participation in these sessions. In addition, please stop by the NLA booth #818 and bring by your colleagues, or encourage them to stop by to learn more about the NLA and becoming a member. You are our best recruiting tool! If you are active on social media, please use the hashtag #NLAatAHA when posting relevant content.

Day 1 – Saturday, November 7, 2015

NLA Master Summit - Managing the Challenging HoFH Patient: Academic Insights and Practical Approaches for a Severe Dyslipidemia
8:30 – 11:30 am Rosen Shingle Creek, Sebastian K room

Day 2 – Sunday, November 8, 2015

Session SMP.500 - Circulating Biomarkers of Atherothrombotic Disease: Biology, Prediction, Causality, and Therapeutic Targeting
8:00 – 11:00 am W303

Presentation: Lp(a) and Oxidized Phospholipids
Joseph Witztum, La Jolla, CA

Session SMP.518 New Therapeutic Strategies for Atherosclerosis
8:00 – 11:00 am W205A
Presentation Moderator: Daniel J Rader, Philadelphia, PA

Session SMP.526 Clinical Lipidology Update
8:00 – 11:00 am W202
Presentation Moderator: Vera Bittner, Birmingham, AL

Presentation Familial hypercholesterolemia update
Samuel S Gidding, Wilmington, DE

Presentation Lp(a) - Risk predictor or treatment target?
Borge Nordestgaard, Copenhagen, Denmark

Session APS.01.01 New Insights into Treatment of Cardiovascular Disease
9:00 am – 6:45 pm A2, Basic Science

Presentation Poster Professor 5:30 - 6:45 pm
Henry N Ginsberg, New York, NY Display Abstract

Session ATE.154 Advances in Identifying and Treating Familial Hyperlipidemia
3:45 – 5:00 pm W209AB

Presentation What's New in Familial Hypercholesterolemia Guidelines
Joshua Knowles, Stanford, CA
Presentation Novel Therapies in Patients with Resistant Famial Hypercholesterolemia - Which to Use and When to Use Them?
Matthew Ito, Bridgewater, NJ

Day 3 – Monday, November 9, 2015

Session APS.84.02 Lipid and Lipoprotein Metabolism: Therapeutics
9:00 – 6:45 pm A2, Population Science

Presentation Compositional Lipoprotein Changes with Omega-3 Carboxylic Acids in Patients with Hypertriglyceridemia Paired with Low HDL-C: A Substudy From the ESPRIT Trial

Session APS.85.04 Lipid Therapy, Quality, and Outcomes
9:00 – 6:45 pm A2, Population Science

Presentation Frequency and Practice Level Variation in Statin Use Among Patients with Diabetes: Insights From the NCDR® PINNACLE Registry
Yashashwi Pokharel, Baylor Coll of Med, Houston, TX; et al.

Session ATE.117 Evaluation and Rx of the Patient with a Family History of Premature CAD
10:45 – 12:00 pm W304CD
Presentation Moderator: Joshua Knowles, Stanford, CA

Presentation Lipid Disorders
Emil Degoma, Philadelphia, PA

Session LBCT.02 Decreasing the Global Burden of Disease: Breakthroughs in Prevention
10:45 – 11:55 am Hall D

Presentation Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
Silvio E Inzucchi, Yale Univ Sch of Med, New Haven, CT; et al.

Session LBCT.05 SPRINT Trial Results: Latest News in Hypertension Management
2:00 – 3:15 pm Hall D

Systolic Blood Pressure Intervention Trial (SPRINT)
Paul K Whelton, New Orleans, LA

What is the Role of Nonstatins in the Statin Era?
2:00 – 3:15 pm Chapin Theater

Session AOS.18.02 Lipoprotein Modifying Therapies
5:30 – 6:45 pm W207

Presentation Incrementally Lowers Low Density Lipoprotein-cholesterol in Patients with Hypercholesterolemia Receiving Stable Statin Therapy
Christie M Ballantyne, Baylor Coll of Med and Houston Methodist DeBakey Heart and Vascular Ctr, Houston, TX; et al.

Day 4 – Tuesday, November 10, 2015

Session AOS.21.02 The Highs and Lows of LDL Cholesterol
9:00 – 10:15 am W202

Presentation No Changes in Average Lipid Profiles in the United States From 2003 to 2012: The National Health and Nutrition Examination Survey 2003-2012
Peter Toth, Baltimore, MD
Presentation LDL-C Levels and Treatment Patterns Among Adults with Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry
Emil M deGoma

Session APS.91.08 Epidemiology and Population Studies VIII
9:00 – 6:45 pm A2, Population Science

Presentation Lomitapide Observational Worldwide Evaluation Registry (LOWER): One-year Data
Dirk Blom, Univ of Cape Town, Cape Town, South Africa; et al.

Session QCOR.06 QCOR 2015 Abstract Poster Session
9:00 – 5:00 Valencia Ballroom - W415AB

Presentation A Novel Cost Effectiveness Model of Eicosapentaenoic Acid (EPA) for Secondary Prevention in the United States
Jordana K Schmier, Carolyn Hulme-Lowe, Exponent, Alexandria, VA; et al.

Session CVS.378 Informing the Clinician-Patient Discussion: Refining ASCVD Risk Prediction
2:00 – 3:15 pm W209AB

Presentation After 2013 ACC/AHA prevention guidelines: Best strategy for CAC
Roger Blumenthal, Baltimore, MD

Presentation Lp(a) - role in refining risk prediction
Peter Willeit, Cambridge, United Kingdom

Presentation Incorporating social characteristics Into treatment decisions
Anthony S Wierzbicki, London, United Kingdom

Session CS.03 Managing Risk Factors for CAD—Clinical Trial Updates
3:45 – 5:03 pm Chapin Theater

Presentation Cholesterol Treatment Targets and Clinical Outcomes: A JUPITER Trial Update
Paul M Ridker, Samia Mora, Lynda Rose, Brigham & Womens Hosp, Boston, MA; on behalf of the JUPITER Trial Study Group

Presentation Relationship Between High-Density Lipoprotein Cholesterol and Cardiovascular and Non-Cardiovascular Mortality: A Population-Based Study of More than 630,000 Individuals Without Prior Cardiovascular Conditions in Ontario, Canad
Dennis T Ko, Inst for Clinical Evaluative Sciences (ICES), Toronto, ON, Canada; et al.

Day 5 – Wednesday, November 11, 2015

Session LBCT.04Novel Therapies for Common Problems
10:45 – 12:15 pm Chapin Theater

Presentation ALN-PCSsc, an RNAi Investigational Agent That Inhibits PCSK9 With Potential for Effective Quarterly or Possibly Bi-Annual Dosing: Results of Single-Blind, Placebo-Controlled, Phase 1 Single-Ascending Dose (SAD), and Multi-Dose (MD) Trial in Adults With Elevated LDL-C, on and off Statins
Kevin Fitzgerald, Alnylam Pharmaceuticals, Cambridge, MA; et al.